Endostatin-expressing endometrial mesenchymal stem cells inhibit angiogenesis in endometriosis through the miRNA-21-5p/TIMP3/PI3K/Akt/mTOR pathway
Stem Cells Translational Medicine · 11.02.2025 · 14 (2)
DOI: 10.1093/stcltm/szae079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 26.11.2024. Verfasst von Yan Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin 150001, Heilo…. Hauptthemen laut MEDLINE: Endometriosis, Endostatins, MicroRNAs, Mesenchymal Stem Cells. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Heilongjiang Province of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Endometriosis is a chronic inflammatory and neoangiogenic disease. Endostatin is one of the most effective inhibitors of angiogenesis. Mesenchymal stem cells (MSCs) have been investigated as compelling options for cell therapy. However, the effect and mechanism of action of endostatin-expressing endometrial MSCs (EMSCs) in endometriosis are unclear. Here, EMSCs were genetically modified to overexpress endostatin (EMSCs-Endo). A reduction in the angiogenic capacity of HUVECs was observed in vitro after treatment with EMSCs-Endo. EMSCs-Endo significantly suppressed endometriotic lesion growth in vivo. The limited efficacy was associated with suppressed angiogenesis. The miRNA-21-5p level and the levels of p-PI3K, p-mTOR, and p-Akt in HUVECs and mouse endometriotic lesions significantly decreased after treatment with EMSCs-Endo, whereas TIMP3 expression significantly increased. In summary, targeted gene therapy with EMSCs-Endo is feasible, and its efficacy in regulating endometriosis can be attributed to the inhibition of angiogenesis, suggesting that EMSCs could be used as promising vehicles for targeted gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin 150001, Heilongjiang, China.
- Department of Mathematical and Statistical Sciences, University of Alberta, Edmonton, Alberta T6G 2G1, Canada.
- Department of Obstetrics and Gynecology Ultrasound, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin 150001, Heilongjiang, China.
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, No. 157, Baojian Road, Nangang District, Harbin 150081, Heilongjiang, China.
ORCID-Profile: Guangmei Zhang
Förderung
- National Natural Science Foundation of China
- Key Research and Development Program of Heilongjiang Province of China
- China Postdoctoral Science Foundation
- First Affiliated Hospital of Harbin Medical University
Zitieren
APA
Cheng, Y., Guo, Q., Cheng, Y., Wang, D., Sun, L., Liang, T., Wang, J., Wu, H., Peng, Z., & Zhang, G. (2025). Endostatin-expressing endometrial mesenchymal stem cells inhibit angiogenesis in endometriosis through the miRNA-21-5p/TIMP3/PI3K/Akt/mTOR pathway. Stem Cells Translational Medicine, 14(2). https://doi.org/10.1093/stcltm/szae079
Vancouver
Cheng Y, Guo Q, Cheng Y, Wang D, Sun L, Liang T, et al. Endostatin-expressing endometrial mesenchymal stem cells inhibit angiogenesis in endometriosis through the miRNA-21-5p/TIMP3/PI3K/Akt/mTOR pathway. Stem Cells Translational Medicine. 2025;14(2). doi:10.1093/stcltm/szae079
BibTeX
@article{Cheng2025,
author = {Cheng, Yan and Guo, Qiuyan and Cheng, Yulei and Wang, Dejun and Sun, Liyuan and Liang, Tian and Wang, Jing and Wu, Han and Peng, Zhibin and Zhang, Guangmei},
title = {Endostatin-expressing endometrial mesenchymal stem cells inhibit angiogenesis in endometriosis through the miRNA-21-5p/TIMP3/PI3K/Akt/mTOR pathway},
journal = {Stem Cells Translational Medicine},
year = {2025},
volume = {14},
number = {2},
doi = {10.1093/stcltm/szae079}
}
EUVIMED